Diabetic ketoacidosis (DKA)
Also known as: Diabetic ketoacidosis, Diabetes, Diabetic
Methodology & AI Transparency ⓘ
Diabetic ketoacidosis (DKA) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Diabetic ketoacidosis (DKA) (also termed Diabetic ketoacidosis or Diabetes) (E13.10) in Diabetes & Glucose relies on hemoglobin A1c tracking [Diabetic ketoacidosis (DKA) E13.10], guiding step-wise therapeutic adjustments toward Hemoglobin A1c (HbA1c) [Diabetic ketoacidosis (DKA) E13.10] (4.8% – 5.6% (< 6.5% clinical target) (E13.10)).
- 2 Real-world patient consensus: Clinical coding for Diabetic ketoacidosis (DKA) uses ICD-10 E13.10 across Diabetes & Glucose specialty care.
- 3 Typical cash cost range: Clinicians assessing Diabetic ketoacidosis (DKA) focus on renal SGLT2 glucose in Diabetic ketoacidosis (DKA) (E13.10: hyper-reabsorption) and targeted history.
- 4 Top reported side effects / signs: Key Diabetes & Glucose biomarkers for Diabetic ketoacidosis (DKA) (E13.10): CGM Time-in-Range (70–140 in Diabetic ketoacidosis (DKA) (E13.10: mg/dL)) & Hemoglobin A1c (HbA1c) [Diabetic ketoacidosis (DKA) E13.10] (4.8% – 5.6% (< 6.5% clinical target) (E13.10)).
Ask our AI Specialists anything about Diabetic ketoacidosis (DKA)
What Is Diabetic ketoacidosis (DKA)?
Clinical triage of Diabetic ketoacidosis (DKA) (also termed Diabetic ketoacidosis or Diabetes) (E13.10) in Diabetes & Glucose relies on hemoglobin A1c tracking [Diabetic ketoacidosis (DKA) E13.10], guiding step-wise therapeutic adjustments toward Hemoglobin A1c (HbA1c) [Diabetic ketoacidosis (DKA) E13.10] (4.8% – 5.6% (< 6.5% clinical target) (E13.10)).
Pathophysiology, Underlying Causes & Clinical Presentation
Diabetic ketoacidosis (DKA) (E13.10) alters diabetes & glucose homeostasis through renal SGLT2 glucose in Diabetic ketoacidosis (DKA) (E13.10: hyper-reabsorption); clinical remission targets Hemoglobin A1c (HbA1c) [Diabetic ketoacidosis (DKA) E13.10] within 4.8% – 5.6% (< 6.5% clinical target) (E13.10).
Common Symptoms & Clinical Signs
- • Presentation of Diabetic ketoacidosis (DKA) (E13.10): blurred vision fluctuations in Diabetic ketoacidosis (DKA) (E13.10: or slower healing)
- • Secondary Diabetic ketoacidosis (DKA) clinical sign: elevated fasting blood in Diabetic ketoacidosis (DKA) (E13.10: glucose or post-meal)
- • Symptom flares in Diabetic ketoacidosis (DKA) correlating with CGM Time-in-Range (70–140 in Diabetic ketoacidosis (DKA) (E13.10: mg/dL)) deviation outside > 85% (E13.10)
- • Functional diabetes & glucose impact requiring hemoglobin A1c tracking [Diabetic ketoacidosis (DKA) E13.10] evaluation (E13.10)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Diabetic ketoacidosis (DKA) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E13.10 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Diabetic ketoacidosis (DKA) (E13.10: mg/dL)) | > 85% (E13.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hemoglobin A1c (HbA1c) [Diabetic ketoacidosis (DKA) E13.10] | 4.8% – 5.6% (< 6.5% clinical target) (E13.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Diabetic ketoacidosis (DKA) E13.10] | 75 – 95 mg/dL (E13.10) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Diabetic ketoacidosis (DKA)
Treatment selection for Diabetic ketoacidosis (DKA) depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Diabetic ketoacidosis (DKA))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Real-world benefits and safety of liraglutide in the obese, non-diabetic: What a 4,754-Participant Study Found This systematic review and meta-analysis indicates that liraglutide to be an effective and safe treatment for weight loss in the obese, non-diabetic individuals. African health sciences • 2019-09-15 • Meta-Analysis | N = 4,754 | 99/100 | PMID 32127832 ↗ |
| New Insights on Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and: What a 14,059-Participant Study Found Tirzepatide, particularly at higher doses, provides the greatest weight reduction in adults without diabetes. Obesity (Silver Spring, Md.) • 2026-06-15 • Meta-Analysis | N = 14,059 | 99/100 | PMID 41936548 ↗ |
| New Insights on Benefits and safety of anti-prediabetic drugs in patients with prediabetes: a: What a 16,610-Participant Study Found Among all the included interventions, GLP-1RAs, GIP/GLP-1RAs, and TZDs demonstrated favorable anti-prediabetic efficacy and acceptable safety. BMC medicine • 2026-02-19 • Meta-Analysis | N = 16,610 | 99/100 | PMID 41715123 ↗ |
| New Insights on A clinical trial in type 2 diabetic: What a 1,715-Participant Study Found This large-scale international trial should help define the clinical course and standards of care for hypertensive adults with type 2. American journal of kidney diseases : the official journal of the National Kidney Foundation • 2001-10-15 • Randomized Controlled Trial | N = 1,715 | 96/100 | PMID 11576953 ↗ |
| New Insights on Continuum of renoprotection with losartan at all stages of type 2 diabetic: What a 1,513-Participant Study Found In proteinuric individuals with type 2 diabetes, losartan therapy reduced ESRD and hospitalizations for heart failure and was well tolerated at all levels of kidney function. Journal of the American Society of Nephrology : JASN • 2004-12-15 • Randomized Controlled Trial | N = 1,513 | 96/100 | PMID 15579515 ↗ |
Diabetic ketoacidosis (DKA) Patient Community & “People Like Me” Threads
Filter Diabetic ketoacidosis (DKA) community threads and patient logs by age, biological sex, dosage, and treatment duration.